Ischemic stroke generates an immune response that contributes to neuronal loss as well as
tissue repair. This is a complex process involving a range of cell types and effector …

Cerebral ischemia is caused by perturbations in blood flow to the brain that trigger
sequential and complex metabolic and cellular pathologies. This leads to brain tissue …

Stroke is a devastating disease with high morbidity and mortality. Animal models are
indispensable tools that can mimic stroke processes and can be used for investigating …

Recombinant human tissue plasminogen activator (rh-tPA) is an important thrombolytic
agent for treatment of acute ischemic stroke. It requires fibrin binding for plasminogen …

Stroke volume is a key determinant of infarct severity and an important metric for evaluating
treatments. However, accurate estimation of stroke volume can be challenging, due to the …

Despite recent advances in recanalization therapy, mechanical thrombectomy will never be
a treatment for every ischemic stroke because access to mechanical thrombectomy is still …

Sonothrombolysis with recombinant tissue plasminogen activator (rtPA) and microbubbles
has been widely studied to enhance thrombolytic potential. Here, we report different …

Ischemic stroke is a leading cause of death and disability. However, very few
neuroprotective agents have shown promise for treatment of ischemic stroke in clinical trials …

Stroke is a major cause of morbidity worldwide; yet, there is a lack of treatment options to
address post-stroke cognitive and motor impairment, thus there is an urgency for developing …

Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for
acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic …